2025-12-31 - Analysis Report
Okay, here's a breakdown of the provided data for Johnson & Johnson (JNJ) along with analysis.

**0) Report Structure**

We'll start with the simple numbers, then provide a basic analysis for each section, and finally, a comprehensive summary.

**1) Return Rate vs. S&P 500 (VOO)**

*   **Ticker:** JNJ
*   **Company Name:** Johnson & Johnson
*   **Overview:** Johnson & Johnson is a global healthcare company engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field.
*   **JNJ Cumulative Return:** 59.46%
*   **VOO Cumulative Return:** 102.21%
*   **Divergence:**
    *   Current: -43.2
    *   Min: -65.5
    *   Max: 16.6
    *   Relative Divergence: 27.2

*   **Analysis:**  JNJ has significantly underperformed the S&P 500 (VOO) over the given period. The current divergence is -43.2%, meaning the cumulative return of JNJ is 43.2 percentage points lower than VOO. The relative divergence of 27.2 suggests that the current divergence is near the lower end of its historical range, meaning the underperformance is relatively high compared to the past.

**Alpha, Beta Analysis & CAGR/MDD**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 26.0% | 66.8% | -2.0% | -0.1 | 336.6 |
| 2016-2018  | 14.0% | 10.7% | -1.0% | 0.1 | 310.9 |
| 2017-2019  | 20.0% | 71.5% | -2.0% | 0.4 | 351.4 |
| 2018-2020  | 19.0% | 79.2% | -4.0% | 0.4 | 379.2 |
| 2019-2021  | 33.0% | 79.2% | -14.0% | 0.5 | 412.2 |
| 2020-2022  | 8.0% | 79.6% | 9.0% | 0.4 | 425.6 |
| 2021-2023  | -19.0% | 79.6% | -20.0% | 0.3 | 377.6 |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3 | 348.4 |
| 2023-2025  | 31.0% | 79.6% | -36.0% | 0.1 | 498.5 |

*   **CAGR (Compound Annual Growth Rate):** Varies significantly, with positive growth in most periods, but negative in recent years.
*   **MDD (Maximum Drawdown):**  High across all periods, indicating significant potential for losses. Notably high in recent years, clustering around 79%.
*   **Alpha:**  Mostly negative, indicating underperformance relative to its benchmark, with a notable positive alpha only in 2020-2022. Negative Alpha values outweigh the positive value.
*   **Beta:** Generally low (around 0.1-0.5), suggesting lower volatility than the market.
*   **Cap(B):** Shows the company's market capitalization in Billions.

*   **Analysis:** The data suggests JNJ has experienced volatile performance in recent years. The high MDD values are concerning, particularly in the context of generally negative alpha. While Beta suggests lower volatility, the significant drawdowns indicate substantial risk. The capital has been consistently increasing over the long-term, but the CAGR, Alpha, Beta values tell a bigger picture.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 206.91
*   **Previous Close:** 207.56
*   **Change:** -0.31
*   **5-day SMA:** 207.13
*   **20-day SMA:** 206.84
*   **60-day SMA:** 198.07

*   **Analysis:** The stock price has seen a slight decrease. The 5-day and 20-day SMAs are close, suggesting short-term stability.  The 60-day SMA is significantly lower, indicating an upward trend over the past two months despite the recent fluctuations.

**3) RSI, PPO, and Market Risk Indicators**

*   **MRI:** 0.9 (Medium Investment)
*   **RSI:** 61.81 (Approaching overbought territory)
*   **PPO:** -0.35 (Slightly bearish)
*   **Hybrid Signal:** Buy 90% of cash (1 share - Safe - MRI:0.80)
*   **Recent Divergence Change (20 days):** -5.7 (Short-term decline)
*   **Expected Return:** -65.2% (Negative)

*   **Analysis:** The MRI suggests a medium investment recommendation. The RSI is approaching overbought, indicating the stock might be due for a correction. The negative PPO supports this bearish sentiment. The negative recent divergence change and highly negative expected return are concerning, suggesting a potentially unfavorable outlook for JNJ.  Despite the hybrid signal recommending a buy, the other indicators paint a cautionary picture.

**4) Recent News & Significant Events**

*   **Key Headlines:**
    *   Halda cancer deal closes; Barclays lifts target
    *   Upside potential for JNJ in 2026
    *   Institutional investors increasing stakes
    *   Deprince Race & Zollo Inc. sold JNJ shares
    *   Expectations for JNJ stock
    *   Barclays raised target price to $217 from $197

*   **Analysis:** News is mixed. The raised target price from Barclays is positive, as is the interest from institutional investors. However, the sale of shares by Deprince Race & Zollo and the closing of the Halda cancer deal could be viewed as negative or neutral, respectively. The general outlook seems cautiously optimistic, with analysts seeing potential upside.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (2.16)
*   **Opinions:** 24
*   **Target Price:**
    *   Average: 210.13
    *   High: 240.00
    *   Low: 155.00
*   **Recent Rating Changes:** No specific changes listed.

*   **Analysis:** Analyst consensus is generally positive, with a "Buy" rating. The average target price is slightly above the current price, suggesting potential upside. The wide range between high and low target prices reflects uncertainty among analysts.

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue    |
|------------|------|------------|
| 2025-10-22 | 2.14 | 23.99 B$   |
| 2025-07-24 | 2.3  | 23.74 B$   |
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2025-10-22 | 1.12 | 22.47 B$   |

*   **Analysis:**  Revenue is generally increasing, with some fluctuations.  EPS has been inconsistent, with a high in April 2025 and then decreasing in the following quarters. The last two lines are redundant and probably contain data errors.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-09-30 | $23.99B   | 69.56%        |
| 2025-06-30 | $23.74B   | 67.87%        |
| 2025-03-31 | $21.89B   | 66.40%        |
| 2024-12-31 | $22.52B   | 68.35%        |
| 2024-09-30 | $22.47B   | 69.01%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE   |
|------------|------------|-------|
| 2025-09-30 | $79.28B   | 6.50% |
| 2025-06-30 | $78.47B   | 7.06% |
| 2025-03-31 | $78.11B   | 14.08%|
| 2024-12-31 | $71.49B   | 4.80% |
| 2024-09-30 | $70.16B   | 3.84% |

*   **Analysis:** Revenue has generally increased over the past year. Profit margins are consistently high, suggesting strong operational efficiency. Equity has steadily increased, reflecting growth in the company's net assets. ROE (Return on Equity) has fluctuated, with a high in March 2025, but generally shows good profitability.

**7) Comprehensive Analysis (Summary)**

Johnson & Johnson (JNJ) presents a mixed picture. While it has a strong financial foundation with growing revenue, high profit margins, and increasing equity, its stock performance has significantly lagged the S&P 500.  Recent performance indicators like negative alpha and expected return, coupled with high maximum drawdowns, raise concerns.

*   **Positives:**
    *   Solid revenue and profit margins.
    *   Increasing equity.
    *   Analyst consensus is "Buy."
    *   Institutional investors are increasing stakes.

*   **Negatives:**
    *   Significant underperformance compared to the S&P 500.
    *   High maximum drawdowns.
    *   Negative alpha, Beta values.
    *   Negative expected return.
    *   The stock is slightly trending down.

*   **Overall:**  JNJ appears to be a fundamentally strong company. However, the recent stock performance suggests caution. Potential investors should carefully consider the underperformance, high drawdowns, and negative expected return before investing. The positive analyst ratings and growing institutional interest provide some counterbalance, but the risks are significant.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.